$41.2 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$3.38 BillionTotal revenue in the last quarter.
$702 MillionNet income is all revenues minus all expenses including taxes and interest in the last quarter.
$24.80Earnings per share is the amount of net income that is attributed to each single share outstanding.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
10.29xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$1.04 BillionEarnings before interest expenses and taxes in the last quarter.
7,300The number of full time employees.
At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.
Oppenheimer Stick to Their Buy Rating for BiogenInvesting.com, 2 days ago
Biotech stocks reversed course in the week ended April 16, with the sector rebounding along with the broader market. The week's news flow was fairly light. The American Association of Cancer Resear...Benzinga, 5 days ago
Sage Therapeutics Inc (NASDAQ: SAGE ) and Biogen Inc (NASDAQ: BIIB ) have scored their first but narrow win after signing their $3.1 billion deal last year in November . SAGE-324, the second major ...Benzinga, 10 days ago